Eliem Therapeutics, a clinical stage biotechnology company focused on developing therapies for neuronal excitability disorders, emerged from stealth with $80 million in capital and two drugs that are already in human tests for chronic pain and depression. The Redmond, Washington-based company is led by Seattle biotech veteran Bob Azelby, who previously headed Juno Therapeutics and Alder Biopharmaceuticals.
On the announcement, Azelby commented, “There’s a ton of excitement and capital flowing towards these early-stage neurology companies.”